Allogeneic Epstein Barr Virus-Specific Cytotoxic T-Lymphocytes in Treating Patients With Progressive, Relapsed, or Refractory Hodgkin's Lymphoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Biological therapies use different ways to stimulate the immune system and stop cancer cells from growing. Donor white blood cells that are treated in the laboratory with Epstein-Barr virus may be effective treatment for Hodgkin's lymphoma.

PURPOSE: Phase I trial to study the effectiveness of allogeneic Epstein-Barr virus-specific cytotoxic T cells in treating patients who have progressive, relapsed, or refractory Hodgkin's lymphoma.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Milton S. Hershey Medical Center
• Collaborator: National Cancer Institute (NCI)
• Treatments: Aldesleukin; Fludarabine; Fludarabine phosphate

Criteria

DISEASE CHARACTERISTICS:

• Histologically proven Hodgkin's lymphoma

• Progressive, relapsed, or refractory disease after prior chemotherapy, radiotherapy, and/or stem cell transplantation

• Epstein Barr virus (EBV) positive by immunohistochemical staining for LMP-1 or 2 OR the presence of EBV RNA (EBER)

• Availability of an HLA identical or haploidentical donor for cytotoxic T-lymphocytes, meeting the following criteria:

• EBV seropositive

• HIV negative

• HTLV-1 negative

• Hepatitis B surface antigen and hepatitis B core antibody IgM negative

• Hepatitis C antibody negative

• Must share at least 1 HLA haplotype with donor

PATIENT CHARACTERISTICS:

Age:

• 18 to 75

Performance status:

• Not specified

Life expectancy:

• At least 8 weeks

Hematopoietic:

• Not specified

Hepatic:

• Bilirubin less than 2.0 mg/dL

• SGOT/SGPT less than 2.5 times normal (unless liver metastases are present)

• If there is liver involvement by disease, an obvious relationship between SGOT/SGPT and disease activity is required

• No hepatic dysfunction causing moribundity

Renal:

• Creatinine clearance greater than 50 mL/min

• No renal dysfunction causing moribundity

Cardiovascular:

• No cardiac dysfunction causing moribundity

Pulmonary:

• No pulmonary dysfunction causing moribundity

Other:

• No neurologic dysfunction causing moribundity

• No history of severe transfusion reactions with blood products (including fetal calf serum)

• Not pregnant

PRIOR CONCURRENT THERAPY:

Biologic therapy:

• See Disease Characteristics

Chemotherapy:

• See Disease Characteristics

• No concurrent antimetabolites

Endocrine therapy:

• Not specified

Radiotherapy:

• See Disease Characteristics

Surgery:

• Not specified